Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com

Compass Therapeutics reported encouraging phase 1 data for CTX-8371, with 3 responses among 15 evaluable patients and a 33% overall response rate at the two highest dose levels. The drug was generally well tolerated, with no dose-limiting toxicities and only one asymptomatic Grade 3 lipase increase, while cohort expansions have started in NSCLC, triple-negative breast cancer, and Hodgkin lymphoma. The stock remains under pressure, down 65% year-to-date and trading near $1.93, but the clinical update should support sentiment ahead of additional data in Q4 2026.

Analysis

The market is likely underestimating the optionality embedded in a clean dose-response signal for a checkpoint-refractory bispecific: if the expansion cohorts reproduce even part of this early activity, CMPX shifts from a single-asset “prove it” story to a platform validation event. That matters because in small biotech, valuation often rerates less on median efficacy and more on whether the drug looks durable enough to support combinations, label expansion, and partnering leverage. The strongest second-order beneficiary is not just CMPX equity, but any later-stage PD-1/PD-L1 biology names with weaker mechanistic differentiation, which now face a higher bar for “me-too” narratives.

The key risk is timing mismatch. The next meaningful catalyst is months away, so the stock can still trade like a cash-burn story unless the company can convert this signal into a financing or partnering process before the market forces dilution at depressed levels. If the broader oncology tape weakens or expansion data disappoints in a larger cohort, the reaction could be asymmetric to the downside because current expectations are already low and the balance-sheet runway remains the gating variable, not scientific curiosity.

Contrarian view: the market may be anchoring too heavily on the recent skepticism around the company’s other program and missing that one credible clinical “win” can materially change negotiating power with strategics. For a sub-$500M biotech, even modest partnering economics can recast the entire equity as a royalty-like call option on multiple datasets. The duration profile also matters: durable responses beyond 6-10 months are more valuable than headline ORR, because they improve the odds of a transaction rather than just a trading pop.

Key Decisions for Investors

• Initiate a small tactical long in CMPX for the 1-3 month window into ASCO/expansion updates; use a starter position only, as the setup is binary and dilution risk remains high. Upside is a rerating on credible cohort expansion data; downside is limited by weak near-term fundamentals and financing overhang.
• Buy CMPX call spreads expiring after the Q4 2026 data readout only if the premium is cheap relative to implied volatility; this is a longer-dated catalyst trade where the payoff is concentrated in a true platform-validation rerate rather than incremental data.
• Hedge the long-biotech exposure with a short basket of non-differentiated checkpoint/PD-(L)1 early clinical names if available, as CMPX’s signal raises the bar for similar mechanistic stories and could compress valuations across the sub-sector.
• If CMPX rallies hard on conference presentation hype, fade strength into the event and re-enter only on post-data confirmation; the asymmetry is better after the market proves it is willing to underwrite durability, not just response rate.